GE HealthCare Technologies to Announce Q1 Earnings on April 29
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GEHC?
Source: seekingalpha
- Earnings Announcement: GE HealthCare Technologies is set to release its Q1 2023 earnings report on April 29 before market open, with consensus EPS estimate at $1.05, reflecting a 4.0% year-over-year increase, and revenue expected at $5.03 billion, up 5.2%, providing crucial financial health indicators for investors.
- Historical Performance Review: Over the past two years, GE HealthCare has exceeded EPS estimates 88% of the time and revenue estimates 50% of the time, indicating a strong track record of financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 10 upward revisions and 2 downward adjustments, while revenue estimates experienced 4 upward and 4 downward revisions, reflecting analyst divergence and market uncertainty regarding the company's future performance.
- Market Environment Impact: Amid escalating tensions in the Middle East, the Nasdaq index hit a record high this week, with semiconductor stocks driving this surge, which may positively influence GE HealthCare's stock price, prompting investors to monitor overall market sentiment's potential impact on the upcoming earnings report.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 70.480
Low
80.00
Averages
92.25
High
105.00
Current: 70.480
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GE HealthCare Technologies to Announce Q1 Earnings on April 29
- Earnings Announcement: GE HealthCare Technologies is set to release its Q1 2023 earnings report on April 29 before market open, with consensus EPS estimate at $1.05, reflecting a 4.0% year-over-year increase, and revenue expected at $5.03 billion, up 5.2%, providing crucial financial health indicators for investors.
- Historical Performance Review: Over the past two years, GE HealthCare has exceeded EPS estimates 88% of the time and revenue estimates 50% of the time, indicating a strong track record of financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 10 upward revisions and 2 downward adjustments, while revenue estimates experienced 4 upward and 4 downward revisions, reflecting analyst divergence and market uncertainty regarding the company's future performance.
- Market Environment Impact: Amid escalating tensions in the Middle East, the Nasdaq index hit a record high this week, with semiconductor stocks driving this surge, which may positively influence GE HealthCare's stock price, prompting investors to monitor overall market sentiment's potential impact on the upcoming earnings report.
See More
U.S. Stocks Near All-Time Highs as Investors Eye Tech Giants' Earnings
- Strong Market Performance: The S&P 500 and Nasdaq Composite indices reached new all-time highs in April, rising over 8% and 13% respectively, indicating robust market resilience despite ongoing geopolitical tensions and AI disruption concerns, reflecting investor confidence in tech stocks.
- Earnings Pressure on Tech Giants: Next week, five of the 'Magnificent Seven' companies will report earnings, with market expectations for them to demonstrate sufficient revenue growth to justify their high AI expenditures; Alphabet, Amazon, Meta, and Microsoft have all seen stock price increases of over 10% this month, highlighting the market's keen interest in their performance.
- Federal Reserve Meeting Impact: This is expected to be Jerome Powell's last meeting as chair, with the market widely anticipating that the Fed will keep interest rates unchanged, although rising oil prices could complicate future monetary policy, necessitating close attention to how this dynamic may affect the market.
- Cautious Investor Sentiment: As the traditional market adage 'Sell in May' approaches, investors remain wary of potential downside risks, particularly in light of poor software stock performance and rising oil prices, which could further dampen market sentiment.
See More
GE HealthCare Launches Clinical Trial for Mangaciclanol MRI Agent
- Clinical Trial Launch: GE HealthCare has initiated the international multi-center Phase 2/3 clinical trial for its manganese-based MRI contrast agent, mangaciclanol, at Mayo Clinic in Minnesota, marking the first patient dosing and demonstrating the company's commitment to innovative imaging agents.
- FDA Fast Track Designation: Mangaciclanol has received Fast Track designation from the FDA for use in adults and pediatric patients aged 2 and older, aimed at detecting lesions with abnormal vascularity in the central nervous system and body, highlighting its potential market value.
- Supply Chain Security: Unlike gadolinium, which is a rare-earth metal, manganese is sourced from multiple countries including South Africa, Australia, and Gabon, reducing the risk of supply chain disruptions affecting patient care and enhancing competitive positioning in the market.
- Reduced Environmental Impact: The macrocyclic structure of mangaciclanol minimizes the likelihood of retention in the body, and as manganese is naturally found in water sources, it may mitigate environmental concerns associated with post-patient excretion of contrast media, aligning with sustainability trends.
See More
GE HealthCare (GEHC) Q4 2024 Earnings Transcript
See More
Structural Shift in U.S. Heart Care Market
- Market Growth Potential: The U.S. cardiovascular devices market is projected to grow from $22.08 billion in 2025 to $41.29 billion by 2032, reflecting a nearly 11.3% annual growth rate, indicating significant demand driven by an aging population.
- AI Tool Adoption: Currently, 75% of U.S. health systems are rolling out AI-powered clinical tools, particularly in cardiac imaging and documentation, which will create asymmetric growth opportunities for companies in this sector.
- New Partnership: VentriPoint Diagnostics has secured a new partnership with the Montecristo Group to deploy its AI cardiac imaging platform across Costa Rica, which is expected to enhance the efficiency and accuracy of cardiac disease screening in the region, further expanding market share.
- Technological Advantage: VentriPoint's VMS+™ system converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRIs at a significantly lower cost, which is anticipated to drive the widespread adoption of cardiac diagnostics.
See More
Exxon Mobil Gains from Middle East War Impacting Helium Supply
- Market Opportunity: The ongoing Middle East war has tightened global helium supply, with UBS analysts noting that Exxon Mobil stands to benefit as a net beneficiary of helium market conditions, particularly as Qatar's production is disrupted.
- Production Capacity: Exxon's LaBarge facility in Wyoming is capable of producing approximately 1.4 billion cubic feet of Grade A helium annually, remaining unaffected by Middle Eastern events, and is expected to play a significant role in helium supply for the next eight decades.
- Price Surge: Spot helium prices have soared to $1,000-$1,200 per thousand cubic feet due to the war, up from about $500 under older contracts, with UBS estimating that every $100 increase in prices could add $119 million to Exxon's EBITDA.
- Investment Rating: UBS reiterated a buy rating for Exxon Mobil with a 12-month price target of $171, implying about 5% upside from Monday's close of $163.37, reflecting positive market sentiment regarding the company's growth prospects.
See More
GE HealthCare Technologies to Announce Q1 Earnings on April 29
- Earnings Announcement: GE HealthCare Technologies is set to release its Q1 2023 earnings report on April 29 before market open, with consensus EPS estimate at $1.05, reflecting a 4.0% year-over-year increase, and revenue expected at $5.03 billion, up 5.2%, providing crucial financial health indicators for investors.
- Historical Performance Review: Over the past two years, GE HealthCare has exceeded EPS estimates 88% of the time and revenue estimates 50% of the time, indicating a strong track record of financial performance and market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen 10 upward revisions and 2 downward adjustments, while revenue estimates experienced 4 upward and 4 downward revisions, reflecting analyst divergence and market uncertainty regarding the company's future performance.
- Market Environment Impact: Amid escalating tensions in the Middle East, the Nasdaq index hit a record high this week, with semiconductor stocks driving this surge, which may positively influence GE HealthCare's stock price, prompting investors to monitor overall market sentiment's potential impact on the upcoming earnings report.
See More
U.S. Stocks Near All-Time Highs as Investors Eye Tech Giants' Earnings
- Strong Market Performance: The S&P 500 and Nasdaq Composite indices reached new all-time highs in April, rising over 8% and 13% respectively, indicating robust market resilience despite ongoing geopolitical tensions and AI disruption concerns, reflecting investor confidence in tech stocks.
- Earnings Pressure on Tech Giants: Next week, five of the 'Magnificent Seven' companies will report earnings, with market expectations for them to demonstrate sufficient revenue growth to justify their high AI expenditures; Alphabet, Amazon, Meta, and Microsoft have all seen stock price increases of over 10% this month, highlighting the market's keen interest in their performance.
- Federal Reserve Meeting Impact: This is expected to be Jerome Powell's last meeting as chair, with the market widely anticipating that the Fed will keep interest rates unchanged, although rising oil prices could complicate future monetary policy, necessitating close attention to how this dynamic may affect the market.
- Cautious Investor Sentiment: As the traditional market adage 'Sell in May' approaches, investors remain wary of potential downside risks, particularly in light of poor software stock performance and rising oil prices, which could further dampen market sentiment.
See More
GE HealthCare Launches Clinical Trial for Mangaciclanol MRI Agent
- Clinical Trial Launch: GE HealthCare has initiated the international multi-center Phase 2/3 clinical trial for its manganese-based MRI contrast agent, mangaciclanol, at Mayo Clinic in Minnesota, marking the first patient dosing and demonstrating the company's commitment to innovative imaging agents.
- FDA Fast Track Designation: Mangaciclanol has received Fast Track designation from the FDA for use in adults and pediatric patients aged 2 and older, aimed at detecting lesions with abnormal vascularity in the central nervous system and body, highlighting its potential market value.
- Supply Chain Security: Unlike gadolinium, which is a rare-earth metal, manganese is sourced from multiple countries including South Africa, Australia, and Gabon, reducing the risk of supply chain disruptions affecting patient care and enhancing competitive positioning in the market.
- Reduced Environmental Impact: The macrocyclic structure of mangaciclanol minimizes the likelihood of retention in the body, and as manganese is naturally found in water sources, it may mitigate environmental concerns associated with post-patient excretion of contrast media, aligning with sustainability trends.
See More
GE HealthCare (GEHC) Q4 2024 Earnings Transcript
See More
Structural Shift in U.S. Heart Care Market
- Market Growth Potential: The U.S. cardiovascular devices market is projected to grow from $22.08 billion in 2025 to $41.29 billion by 2032, reflecting a nearly 11.3% annual growth rate, indicating significant demand driven by an aging population.
- AI Tool Adoption: Currently, 75% of U.S. health systems are rolling out AI-powered clinical tools, particularly in cardiac imaging and documentation, which will create asymmetric growth opportunities for companies in this sector.
- New Partnership: VentriPoint Diagnostics has secured a new partnership with the Montecristo Group to deploy its AI cardiac imaging platform across Costa Rica, which is expected to enhance the efficiency and accuracy of cardiac disease screening in the region, further expanding market share.
- Technological Advantage: VentriPoint's VMS+™ system converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRIs at a significantly lower cost, which is anticipated to drive the widespread adoption of cardiac diagnostics.
See More
Exxon Mobil Gains from Middle East War Impacting Helium Supply
- Market Opportunity: The ongoing Middle East war has tightened global helium supply, with UBS analysts noting that Exxon Mobil stands to benefit as a net beneficiary of helium market conditions, particularly as Qatar's production is disrupted.
- Production Capacity: Exxon's LaBarge facility in Wyoming is capable of producing approximately 1.4 billion cubic feet of Grade A helium annually, remaining unaffected by Middle Eastern events, and is expected to play a significant role in helium supply for the next eight decades.
- Price Surge: Spot helium prices have soared to $1,000-$1,200 per thousand cubic feet due to the war, up from about $500 under older contracts, with UBS estimating that every $100 increase in prices could add $119 million to Exxon's EBITDA.
- Investment Rating: UBS reiterated a buy rating for Exxon Mobil with a 12-month price target of $171, implying about 5% upside from Monday's close of $163.37, reflecting positive market sentiment regarding the company's growth prospects.
See More
